UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

The lancet oncology, 2017-06, Vol.18 (6), p.732-742

2017

Volltextzugriff (PDF)

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The lancet oncology, 2017-06, Vol.18 (6), p.743-754

2017

Volltextzugriff (PDF)

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Journal of clinical oncology, 2020-12, Vol.38 (36), p.4274-4282

2020

Volltextzugriff (PDF)

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-06, Vol.15 (7), p.689-699

2014

Volltextzugriff (PDF)

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2565-2572

2020

Volltextzugriff (PDF)

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies

Clinical cancer research, 2010-07, Vol.16 (14), p.3526-3532

2010

Volltextzugriff (PDF)

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update

Journal of clinical oncology, 2022-08, Vol.40 (23), p.JCO2200520-2655

2022

Volltextzugriff (PDF)

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3234-3241

2012

Volltextzugriff (PDF)

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2

Science translational medicine, 2018-03, Vol.10 (432)

2018

Volltextzugriff (PDF)

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2015-11, Vol.112 (46), p.14325-14330

2015

Volltextzugriff (PDF)

The Evolving Landscape of HER2 Targeting in Breast Cancer

JAMA oncology, 2015-11, Vol.1 (8), p.1154

2015

Volltextzugriff (PDF)

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Journal of clinical oncology, 2011-02, Vol.29 (4), p.398-405

2011

Volltextzugriff (PDF)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast cancer research : BCR, 2020-11, Vol.22 (1), p.120-120, Article 120

2020

Volltextzugriff (PDF)

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Journal of clinical oncology, 2010-06, Vol.28 (16), p.2698-2704

2010

Volltextzugriff (PDF)

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations

Journal of clinical oncology, 2016-07, Vol.34 (19), p.2303-2311

2016

Volltextzugriff (PDF)

PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity

Clinical cancer research, 2016-06, Vol.22 (12), p.2993-3004

2016

Volltextzugriff (PDF)

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Clinical cancer research, 2016-07, Vol.22 (13), p.3249-3259

2016

Volltextzugriff (PDF)

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer

Journal of clinical oncology, 2015-04, Vol.33 (10), p.1136-1142

2015

Volltextzugriff (PDF)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1229-1240

2012

Volltextzugriff (PDF)

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases

Nature medicine, 2016-07, Vol.22 (7), p.723-726

2016

Volltextzugriff (PDF)

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

Breast cancer research : BCR, 2020-11, Vol.22 (1), p.131-131, Article 131

2020

Volltextzugriff (PDF)

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

Journal of clinical oncology, 2011-08, Vol.29 (23), p.3126-3132

2011

Volltextzugriff (PDF)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Nature communications, 2023-11, Vol.14 (1), p.7053-7053, Article 7053

2023

Volltextzugriff (PDF)

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor

Cancer cell, 2014-08, Vol.26 (2), p.222-234

2014

Volltextzugriff (PDF)

1 – 25 von 296

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(293)
Mit Volltextzugriff
(254)

Publikationsform

Artikel
(296)

Sprache

Englisch
(296)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(142)
Life Sciences & Biomedicine
(134)
Oncology
(122)
Humans
(118)
Female
(107)
Breast Neoplasms - Drug Therapy
(82)
Breast Cancer
(63)
Middle Aged
(60)
Adult
(59)
Aged
(54)
Breast Neoplasms - Pathology
(54)
Tumors
(51)
Trastuzumab
(46)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(37)
Breast Neoplasms - Metabolism
(31)
Receptor, Erbb-2 - Metabolism
(30)
Treatment Outcome
(29)
Erbb-2 Protein
(28)
Metastasis
(28)
Breast Neoplasms - Genetics
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

The Evolving Landscape of HER2 Targeting in Breast Cancer

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations

PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor

Suchergebnisse filtern